CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of CD20 to construct vaccines for B-cell-related disorders. The immunogenicity of the vaccines was tested in BALB/c mice. Results of this study suggest that the mimotope may be a useful tool for the construction of a functional vaccine to treat B cell-related disorders.
Keywords: CD20, mimotope, vaccine, B-cell lymphoma, immunotherapy, keyhole limpet hemocyanin (KLH)
Rights & PermissionsPrintExport